Omeros Corporation (OMER)

Market Cap	801.20M +123.3%
Revenue (ttm)	9.89M
Net Income	86.17M
EPS	1.21
Shares Out	72.38M
PE Ratio	9.16
Forward PE	24.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,355,445
Open	11.77
Previous Close	11.65
Day's Range	10.55 - 12.02
52-Week Range	2.95 - 17.65
Beta	2.66
Analysts	Buy
Price Target	33.50 (+202.62%)
Earnings Date	May 13, 2026

About OMER

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2009
• Employees: 175
• Stock Exchange: NASDAQ
• Ticker Symbol: OMER
• Website: https://www.omeros.com

Analyst Summary

According to 4 analysts, the average rating for OMER stock is "Buy." The 12-month stock price target is $33.5, which is an increase of 202.62% from the latest price.

Price Target

$33.5

(202.62% upside)

Analyst Consensus: Buy